As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000’s recent underperformance. Amidst these dynamics, high growth tech stocks such as Shanghai Henlius Biotech stand out by leveraging innovation and adaptability to navigate economic shifts and investor expectations.
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
---|---|---|---|
Material Group |
20.45% |
24.01% |
★★★★★★ |
Yggdrazil Group |
30.20% |
87.10% |
★★★★★★ |
Seojin SystemLtd |
35.41% |
39.86% |
★★★★★★ |
eWeLLLtd |
27.24% |
28.74% |
★★★★★★ |
Medley |
25.57% |
31.67% |
★★★★★★ |
Waystream Holding |
22.09% |
113.25% |
★★★★★★ |
Mental Health TechnologiesLtd |
25.83% |
113.12% |
★★★★★★ |
CD Projekt |
24.92% |
27.00% |
★★★★★★ |
Fine M-TecLTD |
36.52% |
131.08% |
★★★★★★ |
JNTC |
29.48% |
104.37% |
★★★★★★ |
Click here to see the full list of 1267 stocks from our High Growth Tech and AI Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12.96 billion.
Operations: Henlius generates revenue primarily from its pharmaceuticals segment, amounting to CNÂ¥5.64 billion. The company is involved in the development of biologic medicines across key therapeutic areas.
Shanghai Henlius Biotech’s recent advancements underscore its strategic focus on developing innovative therapies in the biotech sector. With a revenue growth of 9.8% and earnings growth forecast at 11.92% per year, the company is outpacing the Hong Kong market averages significantly, suggesting robust operational execution. Notably, its R&D efforts are pivotal, highlighted by the approval of HLX22 for phase 2 trials and HLX43 targeting PD-L1, positioning it at the forefront of cancer treatment innovations. These developments reflect a promising trajectory in addressing complex medical needs while expanding its influence in global markets through strategic product pipelines and clinical trials.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Visual China Group Co., Ltd. operates as an internet media service provider both in China and internationally, with a market capitalization of CNÂ¥21 billion.
Operations: Visual China Group Co., Ltd. generates revenue through its internet media services, serving both domestic and international markets. The company leverages digital platforms to offer a range of media content and related services, contributing to its market presence in the industry.